

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Linda B. Couto *et al.*

Serial No.: 09/470,618

Group No.: 1633

Filed: 12/22/99

Examiner: Nikodem

Entitled: **ADENO-ASSOCIATED VECTORS FOR
EXPRESSION OF FACTOR VIII BY
TARGET CELLS**

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF HAND DELIVERY	
I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being hand delivered in an envelope addressed to Examiner D. Nikodem.	
Dated: <u>October 24, 2000</u>	By: <u>Jane Edwards</u> Jane Edwards

Sir or Madam:

In compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97, Applicants herewith submit this Information Disclosure Statement and accompanying Form PTO-1449.


In accordance with 37 C.F.R. § 1.98(d), Applicants respectfully request that all citations in the Information Disclosure Statement and Form PTO-1449 (filed on November 18, 1999) entered in the record of U.S. Patent Application No. 09/364,862, be made of official record in this Application. The present Application claims priority to Application No. 09/364,862, and each reference cited and provided in that Information Disclosure Statement and Form PTO-1449 may be material to the examination of the present Application.

Furthermore, Applicants have become aware of the following printed publications, copies attached, which are considered in the corresponding 37 U.S.C. § 371 Application Search Report, and may be material to the examination of the present Application:

- Connelly *et al.*, "Complete Short-Term Correction of Canine Hemophilia A by In Vivo Gene Therapy," *Blood* 88(10):3846-3853 (1996);
- Connelly *et al.*, "Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy," *Blood* 91(9):3273-3281 (May 1, 1998)
- Lozier *et al.*, "Gene Therapy and the Hemophilias," *JAMA* 271(1):47-51 (1994);
- Snyder *et al.*, "Persistent and Therapeutic Concentrations of Human Factor IX in Mice after Hepatic Gene Transfer of Recombinant AAV Vectors," *Nature Genetics* 16:270-276 (July 1997);
- Zatloukal *et al.*, "In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery," *Proc. Natl. Acad. Sci. USA* 91:5148-5152 (1994);

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: October 25, 2000


Kamrin T. MacKnight
Registration No. 38,230

MEDLEN & CARROLL, LLP
220 Montgomery Street, Suite 2200
San Francisco, California 94104
415/705-8410